Search

Search Constraints

You searched for: Author/Creator Clamp, Andrew R

Search Results

1. 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. (20th October 2022)

4. Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Issue 2 (February 2021)

5. Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. Issue 5 (25th January 2019)

7. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2020)

8. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Issue 7 (8th June 2021)

9. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression‐free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Issue 7 (July 2021)